The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Corrigan-Curay emphasized that Journavx could “mitigate certain risks associated with using an opioid for pain.” The FDA’s official account on X also tweeted the news — the agency’s ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...

The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.